A detailed history of First National Trust CO transactions in Abb Vie Inc. stock. As of the latest transaction made, First National Trust CO holds 130,650 shares of ABBV stock, worth $21.7 Million. This represents 1.01% of its overall portfolio holdings.

Number of Shares
130,650
Previous 132,836 1.65%
Holding current value
$21.7 Million
Previous $22.8 Million 13.24%
% of portfolio
1.01%
Previous 0.95%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$163.84 - $199.33 $358,154 - $435,735
-2,186 Reduced 1.65%
130,650 $25.8 Million
Q2 2024

Aug 02, 2024

SELL
$154.79 - $180.76 $702,437 - $820,288
-4,538 Reduced 3.3%
132,836 $22.8 Million
Q1 2024

Apr 26, 2024

SELL
$159.82 - $182.1 $592,133 - $674,680
-3,705 Reduced 2.63%
137,374 $25 Million
Q4 2023

Feb 06, 2024

SELL
$137.6 - $154.97 $1.23 Million - $1.39 Million
-8,970 Reduced 5.98%
141,079 $21.9 Million
Q3 2023

Nov 06, 2023

SELL
$133.59 - $154.65 $413,060 - $478,177
-3,092 Reduced 2.02%
150,049 $22.4 Million
Q2 2023

Aug 01, 2023

SELL
$132.51 - $164.9 $88,914 - $110,647
-671 Reduced 0.44%
153,141 $20.6 Million
Q1 2023

Apr 26, 2023

BUY
$144.61 - $166.54 $84,886 - $97,758
587 Added 0.38%
153,812 $24.5 Million
Q4 2022

Feb 02, 2023

BUY
$138.31 - $165.87 $821,976 - $985,765
5,943 Added 4.04%
153,225 $24.8 Million
Q3 2022

Nov 02, 2022

BUY
$134.21 - $153.93 $3.5 Million - $4.01 Million
26,055 Added 21.49%
147,282 $19.8 Million
Q2 2022

Aug 03, 2022

SELL
$137.62 - $174.96 $355,059 - $451,396
-2,580 Reduced 2.08%
121,227 $18.6 Million
Q1 2022

May 03, 2022

BUY
$131.98 - $163.75 $177,249 - $219,916
1,343 Added 1.1%
123,807 $20.1 Million
Q4 2021

Feb 03, 2022

BUY
$107.43 - $135.93 $89,059 - $112,685
829 Added 0.68%
122,464 $16.6 Million
Q3 2021

Nov 05, 2021

SELL
$106.4 - $120.78 $35,963 - $40,823
-338 Reduced 0.28%
121,635 $13.1 Million
Q2 2021

Aug 06, 2021

SELL
$105.21 - $117.21 $463,660 - $516,544
-4,407 Reduced 3.49%
121,973 $13.7 Million
Q1 2021

May 06, 2021

SELL
$102.3 - $112.62 $920,597 - $1.01 Million
-8,999 Reduced 6.65%
126,380 $13.7 Million
Q4 2020

Feb 10, 2021

SELL
$80.49 - $108.67 $55,699 - $75,199
-692 Reduced 0.51%
135,379 $14.5 Million
Q3 2020

Nov 04, 2020

SELL
$85.91 - $100.83 $540,116 - $633,918
-6,287 Reduced 4.42%
136,071 $11.9 Million
Q2 2020

Aug 06, 2020

SELL
$73.37 - $98.18 $129,864 - $173,778
-1,770 Reduced 1.23%
142,358 $14 Million
Q1 2020

Apr 29, 2020

SELL
$64.5 - $97.79 $124,485 - $188,734
-1,930 Reduced 1.32%
144,128 $11 Million
Q4 2019

Feb 04, 2020

BUY
$72.13 - $90.25 $70,038 - $87,632
971 Added 0.67%
146,058 $12.9 Million
Q3 2019

Nov 01, 2019

BUY
$62.98 - $75.72 $468,319 - $563,053
7,436 Added 5.4%
145,087 $11 Million
Q2 2019

Jul 22, 2019

BUY
$65.7 - $83.98 $28,908 - $36,951
440 Added 0.32%
137,651 $10 Million
Q1 2019

Apr 25, 2019

BUY
$77.14 - $90.79 $17,202 - $20,246
223 Added 0.16%
137,211 $11.1 Million
Q4 2018

Jan 28, 2019

BUY
$77.85 - $96.01 $156,322 - $192,788
2,008 Added 1.49%
136,988 $12.6 Million
Q3 2018

Oct 31, 2018

SELL
$88.91 - $98.84 $406,140 - $451,501
-4,568 Reduced 3.27%
134,980 $0
Q2 2018

Jul 30, 2018

BUY
$89.78 - $106.23 $259,015 - $306,473
2,885 Added 2.11%
139,548 $12.9 Million
Q1 2018

Apr 30, 2018

BUY
$92.01 - $123.21 $520,592 - $697,122
5,658 Added 4.32%
136,663 $12.9 Million
Q4 2017

Jan 17, 2018

SELL
$89.56 - $98.21 $94,038 - $103,120
-1,050 Reduced 0.8%
131,005 $12.7 Million
Q3 2017

Nov 06, 2017

BUY
$69.85 - $89.22 $83,470 - $106,617
1,195 Added 0.91%
132,055 $11.7 Million
Q2 2017

Aug 07, 2017

BUY
N/A
130,860
130,860 $9.49 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $294B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track First National Trust CO Portfolio

Follow First National Trust CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First National Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on First National Trust CO with notifications on news.